Silk Road Medial, Inc. is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke.
In April 2011, Warburg Pincus led a Series B financing of Silk Road. Subsequently, Warburg Pincus has continued to invest to support product development and clinical trials of the company’s technology. In April 2019, Silk Road Medical successfully executed its IPO on the NASDAQ.